LONDON, February 16, 2017 /PRNewswire/ --
Prima BioMed maintains its leadership in LAG-3 immunotherapies with the initiation of the randomized Phase IIb component of the AIPAC trial of IMP321 in breast cancer. In addition, the TACTI-Mel study of IMP321 combined with Keytruda in melanoma is expected to complete recruitment and report safety data in mid-2017, while the pipeline now includes a first-in-class Lag-3 agonist antibody. Initial efficacy data on the first 15 patients in AIPAC is also expected mid-year. We have revised development timelines for in-house and partnered LAG-3 programs, which sees our valuation decrease to US$192m or US$9.24/ADR (vs US$215m or US$10.40/ADR).
Our valuation decreases to US$192m (vs US$215m). After reviewing probable development time lines we have delayed forecast market launch dates for each pipeline product by 12 months. Furthermore, we have removed CVac from our valuation model until partner Sydys raises funds to complete development. Our valuation is equal to US$9.24/ADR on an undiluted basis (vs US$10.40) or US$6.37/ADR after accounting for dilution from options, warrants and convertible notes (vs US$7.07).
Click here to view the full report.
All reports published by Edison are available to download free of charge from its website
About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:
For more information please contact:
Dennis Hulme, Edison Investment Research, +61(0)2-9258-1161
Lala Gregorek, Edison Investment Research, +44(0)20-3681-2527
SOURCE Edison Investment Research